51 related articles for article (PubMed ID: 23884781)
21. The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3.
Li J; Li H; Zhang Z; Wang N; Zhang Y
Biol Res; 2016 Mar; 49():21. PubMed ID: 27015938
[TBL] [Abstract][Full Text] [Related]
22. The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.
Dicitore A; Grassi ES; Caraglia M; Borghi MO; Gaudenzi G; Hofland LJ; Persani L; Vitale G
Endocrine; 2016 Jan; 51(1):101-12. PubMed ID: 25863490
[TBL] [Abstract][Full Text] [Related]
23. Trial watch: Immunostimulatory cytokines in cancer therapy.
Vacchelli E; Aranda F; Obrist F; Eggermont A; Galon J; Cremer I; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e29030. PubMed ID: 25083328
[TBL] [Abstract][Full Text] [Related]
24. Interleukins as markers of inflammation in malignant and benign thyroid disease.
Provatopoulou X; Georgiadou D; Sergentanis TN; Kalogera E; Spyridakis J; Gounaris A; Zografos GN
Inflamm Res; 2014 Aug; 63(8):667-74. PubMed ID: 24794392
[TBL] [Abstract][Full Text] [Related]
25. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
Vitale G; Tagliaferri P; Caraglia M; Rampone E; Ciccarelli A; Bianco AR; Abbruzzese A; Lupoli G
J Clin Endocrinol Metab; 2000 Mar; 85(3):983-8. PubMed ID: 10720027
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
Díez JJ; Iglesias P
J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
[TBL] [Abstract][Full Text] [Related]
27. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Faggiano A; Modica R; Severino R; Camera L; Fonti R; Del Prete M; Chiofalo MG; Aria M; Ferolla P; Vitale G; Pezzullo L; Colao A
Endocrine; 2018 Oct; 62(1):46-56. PubMed ID: 29572709
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study.
Dicitore A; Cantone MC; Gaudenzi G; Saronni D; Carra S; Borghi MO; Albertelli M; Ferone D; Hofland LJ; Persani L; Vitale G
Neuroendocrinology; 2021; 111(10):937-950. PubMed ID: 33075795
[TBL] [Abstract][Full Text] [Related]
29. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
[TBL] [Abstract][Full Text] [Related]
31. Medullary thyroid carcinoma and hormones.
Cohen R; Quidville V; Bihan H
Ann Med Interne (Paris); 2003 Mar; 154(2):109-16. PubMed ID: 12746649
[TBL] [Abstract][Full Text] [Related]
32. Update on medullary thyroid cancer.
Hu MI; Ying AK; Jimenez C
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
[TBL] [Abstract][Full Text] [Related]
33. Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):13-5. PubMed ID: 27168107
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
